- Trials with a EudraCT protocol (631)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
631 result(s) found for: multiple sclerosis.
Displaying page 1 of 32.
EudraCT Number: 2011-001160-21 | Sponsor Protocol Number: PDY11684 | Start Date*: 2011-07-18 | |||||||||||
Sponsor Name:sanofi-aventis recherche & developpement | |||||||||||||
Full Title: Study to investigate the immune response to influenza vaccine in patients with multiple sclerosis on teriflunomide treatment and using a population of patients with multiple sclerosis as a reference | |||||||||||||
Medical condition: Multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011516-37 | Sponsor Protocol Number: 14022009 | Start Date*: 2009-05-29 | |||||||||||
Sponsor Name:Danish Multiple Sclerosis Research Centre | |||||||||||||
Full Title: Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multipl... | |||||||||||||
Medical condition: Multiple Sclerosis, with primary and secondary progressive courses. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000503-15 | Sponsor Protocol Number: NEMESI-MS | Start Date*: 2007-02-19 | |||||||||||
Sponsor Name:AZ. OSPEDALIERA GARIBALDI, S.LUIGI CURRO , ASCOLI TOMASELLI | |||||||||||||
Full Title: Experimental clinical open study, randomized, experimental group vs control group, for the evaluation of tolerability and the effects on magnetic resonance parameters and cognitive functions of mem... | |||||||||||||
Medical condition: patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005460-30 | Sponsor Protocol Number: 2004.363/18 | Start Date*: 2007-05-22 | |||||||||||
Sponsor Name:OSPEDALI CIVILI DI LIONE | |||||||||||||
Full Title: POPARTMUS Prevention of Post Partum Relapses with Progestin and Estradiol in Multiple sclerosis | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005414-40 | Sponsor Protocol Number: LEV-SM-2006 | Start Date*: 2007-12-21 | |||||||||||
Sponsor Name:AZIENDA SANITARIA N. 3 GENOVESE | |||||||||||||
Full Title: Efficacy and activity of levetiracetam on Multiple Sclerosis cerebellar symptoms: a multicenters double blind, randomized, placebo-controlled, cross over study | |||||||||||||
Medical condition: Patients with an established and stable Multiple Sclerosis (according to Poser criteria). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001496-11 | Sponsor Protocol Number: 08020 | Start Date*: 2010-01-15 | |||||||||||
Sponsor Name:University of Nottingham | |||||||||||||
Full Title: The Effects of Tetanus Vaccination on Mediators of Autoimmunity in Patients with Multiple Sclerosis | |||||||||||||
Medical condition: Multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023678-38 | Sponsor Protocol Number: GR-2008-1138784 sottostudio | Start Date*: 2011-04-20 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. | |||||||||||||
Medical condition: patients with multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001409-10 | Sponsor Protocol Number: FATIMS1.0 | Start Date*: 2013-08-08 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: FATIMS - Fampyra and T cell Immunity in Multiple Sclerosis; a study of the Fampyra induced immunomodulatory T cell responses in MS | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005148-28 | Sponsor Protocol Number: 25643 | Start Date*: 2005-05-26 | |||||||||||
Sponsor Name:Merck Serono International S.A. | |||||||||||||
Full Title: A phase III, randomised, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral Cladribine in subjects with relapsing remitting multiple sclerosis | |||||||||||||
Medical condition: Relapsing-remitting multiple sclerosis (RRMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) DK (Completed) EE (Completed) CZ (Completed) BE (Completed) IT (Completed) AT (Completed) SK (Completed) LT (Completed) DE (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004019-29 | Sponsor Protocol Number: CAIN457B2203 | Start Date*: 2013-04-29 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose-ranging study to evaluate the efficacy and safety of AIN457 in patients with relapsing multiple ... | |||||||||||||
Medical condition: Relapsing multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) IT (Temporarily Halted) SE (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) FI (Prematurely Ended) ES (Completed) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001286-17 | Sponsor Protocol Number: REMIT0401 | Start Date*: 2006-09-08 | |||||||||||
Sponsor Name:Fundación Española de Esclerosis Múltiple (FEDEM) | |||||||||||||
Full Title: Exploratory trial to evaluate the risk-benefit ratio of the use of mitoxantrone in patients under treatment with high dose interferon-beta-1a for relapsing-remitting or relapsing secondary progresi... | |||||||||||||
Medical condition: Relapsing-remitting or relapsing secondary progressive multiple sclerosis with high activity | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003113-40 | Sponsor Protocol Number: dexameth-001-2006 | Start Date*: 2006-08-18 | |||||||||||
Sponsor Name:Department of Neurology UMCG | |||||||||||||
Full Title: Dexamethason for the treatment of exacerbations in multiple sclerosis | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002626-11 | Sponsor Protocol Number: ITT-PMS | Start Date*: 2009-07-02 | |||||||||||
Sponsor Name:Dept of Neurology | |||||||||||||
Full Title: Intrathecal therapy with monoclonal antibodies in severe progressive multiple sclerosis | |||||||||||||
Medical condition: Severe progressive multiple sclerosis in which there is no other documented treatment avalilable or allready tested. It is estimated that the prognosis for these patients are poor without any effec... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000393-47 | Sponsor Protocol Number: SP000680 | Start Date*: 2004-09-22 | |||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | |||||||||||||
Full Title: Effect of Cannabis Based Medicine Extract Sativex on brain function as assessed by fMRI and neurophysiologic evaluation in patients with Multiple Sclerosis a double blind, randomised, placebo-co... | |||||||||||||
Medical condition: Treatment of spasticity in patients with Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004318-42 | Sponsor Protocol Number: perfusie_pharma | Start Date*: 2006-12-12 | |||||||||||
Sponsor Name:Department of Neurology UMCG | |||||||||||||
Full Title: Influence on brain perfusion and metabolism through pharmacologic agents | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000296-12 | Sponsor Protocol Number: T13/2014 | Start Date*: 2014-04-15 | |||||||||||
Sponsor Name:Turku University Hospital | |||||||||||||
Full Title: | |||||||||||||
Medical condition: Multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000762-13 | Sponsor Protocol Number: TV-5010/202 | Start Date*: 2004-08-31 | |||||||||||
Sponsor Name:TEVA ITALIA srl | |||||||||||||
Full Title: A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis. | |||||||||||||
Medical condition: Subject with relapsing remitting Multiple Sclerosis. Subject must have at least one documented relapse within one year prior to screening visit. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000463-94 | Sponsor Protocol Number: GA/7026 | Start Date*: 2007-07-03 | |||||||||||
Sponsor Name:TEVA Pharmaceutical Industries Ltd. | |||||||||||||
Full Title: A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 600mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (... | |||||||||||||
Medical condition: Relapsing-remitting multiple sclerosis (R-R MS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000759-40 | Sponsor Protocol Number: TV - 5010/201 | Start Date*: 2004-10-22 | |||||||||||
Sponsor Name:TEVA | |||||||||||||
Full Title: A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 15 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis. | |||||||||||||
Medical condition: Subject with relapsing remitting Multiple Sclerosis. Subject must have at least one documented relapse within one year prior to screening visit. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008554-23 | Sponsor Protocol Number: AIR | Start Date*: 2009-12-29 | |||||||||||
Sponsor Name:The Multiple Sclerosis Research Group, Department of Clinical Neuroscience | |||||||||||||
Full Title: Neutralizing Antibodies to Interferon beta in patients treated with Rebif New Formulation | |||||||||||||
Medical condition: IFNβ-naïve patients fulfilling Poser or McDonald criteria for CDMS or MS and in whom a decision has been made to initiate treatment with RNF (Rebif New Formulation). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
